Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||M2698||Phase I||Actionable||In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy in a variety of advanced solid tumor patients (Ann. Oncol. 26 (Suppl 2): ii25-ii27, 2015).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||M2698||Phase I||Actionable||In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy, with 19% (6/32) of advanced solid tumor patients remained on treatment for more than 180 days (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 370PD; NCT01971515).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||M2698||Preclinical||Actionable||In a preclinical study, MSC2363318A demonstrated sustained inhibition of S6K phosphorylation, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).||detail...|
|PubMed Id||Reference Title||Details|
|Abstract A162: Identification of brain penetrant p70S6K/Akt inhibitor MSC2363318A.||Full reference...|
|A FIRST IN HUMAN, DOSE ESCALATION TRIAL OF MSC2363318A - A DUAL P70S6K/AKT INHIBITOR, FOR PATIENTS WITH ADVANCED MALIGNANCIES||Full reference...|
|Phase I dose escalation study of M2698, a p70S6K/AKT inhibitor, in patients with advanced cancer||Full reference...|